IN THE CLAIMS:

This listing of the claims replaces all prior versions of the claims in the application.

1. *(Currently amended)* A method for treating hot flush in a subject, comprising the step of: administering to said subject an effective amount of desipramine ~~a first component which is a selective norepinephrine reuptake inhibitor~~, its derivatives and or pharmaceutically acceptable salts thereof in combination with an effective amount of (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol~~a second component which is a 5-HT$_2$ receptor antagonist~~, its derivatives and or pharmaceutically acceptable salts thereof.

Claims 2 - 13. *(Cancelled)*

14. *(Currently amended)* The method of ~~any one of claims~~ claim 1~~ and 4 to 6~~, wherein the subject is human.

15. *(original)* The method of claim 14, wherein the human is female patient.

16. *(original)* The method of claim 15, wherein the female patient is perimenopausal.

17. *(original)* The method of claim 15, wherein the female patient is menopausal.

18. *(original)* The method of claim 15, wherein the female patient is post-menopausal.

19. *(original)* The method of claim 14, wherein the subject is male patient.

20. *(original)* The method of claim 19, wherein the male patient is naturally, chemically or surgically andropausal.

21. *(Currently amended)* The method of claim 1 ~~4~~, wherein the administration of desipramine ~~norepinephrine reuptake inhibitor~~ and (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol ~~5-HT$_2$ antagonist~~ is concurrent.

22. *(Currently amended)* The method of claim 1 ~~4~~, wherein the administration of desipramine ~~norepinephrine reuptake inhibitor~~ and (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol ~~5-HT$_2$ antagonist~~ is simultaneous.

Claims 23 and 24. *(Cancelled)*